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Recurrent HER2 missense mutations have been reported in human cancers. These
mutations occur primarily in the absence of HER2 gene amplification such that most
HER2 mutant tumors are classified as “negative” by FISH or immunohistochemistry
assays. It remains unclear whether non-amplified HER2 missense mutations are
oncogenic, and whether they are targets for HER2-directed therapies that are currently
approved for the treatment of HER2 gene-amplified breast cancers. Here we
functionally characterize HER2 kinase and extracellular domain mutations through gene
editing of the endogenous loci in HER2 non-amplified human breast epithelial cells. In in
vitro and in vivo assays, the majority of HER2 missense mutations do not impart
detectable oncogenic changes. However, the HER2 V777L mutation increased
biochemical pathway activation and, in the context of a PIK3CA mutation, enhanced
migratory features in vitro. However, the V777L mutation did not alter in vivo
tumorigenicity or sensitivity to HER2-directed therapies in proliferation assays. Our
results suggest the oncogenicity and potential targeting of HER2 missense mutations
should be considered in the context of cooperating genetic alterations and provide new
insights into functional analysis of HER2 mutations and strategies to target them.
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Breast cancer is the most commonly diagnosed cancer in women in the
United States. There are approximately 232,000 new cases diagnosed and
nearly 40,000 deaths each year, making breast cancer the second most common
cause of cancer related deaths among women in the United States (1). The
development of breast cancer is multi-faceted and complex, involving
predisposing inherited genetic alterations, carcinogenic environmental
exposures, and many other factors, but a major cause of breast carcinogenesis
is the accumulation of and selection for tumor-promoting somatic genetic
alterations. Genetic alterations, including mutations, rearrangements, deletions,
and amplifications, of certain genes allow normal cells to undergo transformation
into cancer cells and drive the growth and survival of a tumor (2).
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Across breast cancers, the majority of mutations occur at low frequencies
(i.e. a given mutation occurs in a low percentage of diagnosed breast cancers),
with only a few genes, including PIK3CA and TP53, occurring at relatively higher
frequencies (3-5). However, the high incidence of breast cancer makes the study
of low frequency mutations potentially impactful for tens of thousands of patients
each year. Cancer cells often rely on the action of mutated oncogenes for growth
and survival, making oncogenes an extremely important and promising target for
cancer therapies (6). Characterization of mutations in oncogenes found in breast
cancer can provide understanding into the mechanisms through which these
mutations promote the initiation, growth, and survival of cancer cells. Insights into
how oncogenic mutations drive cancers have led to the development of more
effective and less toxic anti-cancer therapies that shut down the molecular
pathways cancers use to grow and survive (7,8).
Recent cancer genome sequencing studies have demonstrated that
somatic point mutations in the gene HER2 occur in a number of cancers,
including 2-4% of breast cancers (9-12). While there has been extensive work
showing that amplification/overexpression of HER2 can deregulate normal
signaling pathways and promote the formation and growth of malignant tumors,
the functional consequences of HER2 missense mutations remains relatively
unstudied. HER2 mutations cluster in the extracellular and kinase domains of
HER2 and are found at high clonal frequencies in patient tumors, indicating that
they may be driving tumor formation or growth, thus presenting a potential new
target for anti-cancer therapies.
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HER2 background and function
Discovery of HER2
The receptor tyrosine kinase HER2 (encoded by the gene HER2/ErbB2)
has been a focus of cancer research since its discovery in the 1980s. The first
work leading to the discovery of HER2 utilized a calcium-phosphate DNA
precipitation technique to introduce DNA from rat neuro/glioblastoma cells into
NIH3T3 mouse fibroblasts (13,14). The introduction of this DNA resulted in
morphological changes in NIH3T3 cells and promoted a transformed phenotype.
In 1984, cells were transformed by the introduction of mutant rat DNA derived
from carcinogen-induced neuroblastomas (15); the oncogene responsible for this
transformation was the same as previously identified by Shih et al. and was given
the name neu. Neu was later shown to encode a 185 kDa phosphoprotein that
had extensive homology to the kinase domain of the epidermal growth factor
receptor (EGFR/ErbB1) (16). Further work mapped a human ortholog to neu,
HER2, to chromosome 17, distinct from EGFR on chromosome 7 (17).
HER2 gene and protein structure
The HER2 gene is located on chromosome 17q12 and contains 30 exons,
26 of which are coding exons. The predominate HER2 mRNA transcript variant
encodes a 185 kDa receptor tyrosine kinase protein comprised of 1,255 amino
acids. HER2 is a member of the ErbB family of transmembrane receptor tyrosine
kinases which includes the epidermal growth factor receptor (EGFR/ErbB1),
HER3 (ErbB3), and HER4 (ErbB4) (18). These receptors are each comprised of
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five domains including an extracellular domain, a transmembrane domain, a
juxtamembrane region, a tyrosine kinase domain, and a C-terminal regulatory
region (7,19,20). The extracellular domain of ErbB receptors are further divided
into four distinct sub-domains. Typically, sub-domains II and IV interact until the
receptor binds ligand. After ligand is bound, sub-domains I and III are brought
close together, which breaks the interaction between sub-domains II and IV,
allowing sub-domain II to freely facilitate receptor dimerization and initiate signal
transduction (21). In contrast to other ErbB receptors, HER2 is considered an
orphan receptor that does not bind a specific ligand. However, HER2 always
exists in a ligand-activated conformation where extracellular sub-domain II is
available for receptor dimerization (22). This property makes HER2 the preferred
dimerization partner for other ligand bound ErbB receptor family members
(20,23).
The intracellular tyrosine kinase domains of HER2 and other ErbB
receptors are comprised of docking sites for adapter proteins that promote
downstream signaling. Ligand binding and receptor dimerization acts as an
allosteric activator of kinase domain catalytic activity which leads to the
phosphorylation of tyrosine residues in the kinase domain (24). Interestingly,
HER3 lacks certain key residues thought to be required for catalytic activity in the
kinase domain, and recent studies have shown the catalytic activity of HER3 to
be roughly 1,000 fold less than that of EGFR (24,25). Due to this low catalytic
activity, HER3 is thought to function primarily as an allosteric activator in
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asymmetric dimers with other ErbB receptors. In contrast, HER2 has the most
potent tyrosine kinase activity of the ErbB receptors (8).
HER2 mediated signaling
ErbB receptors are activated by ligands including epidermal growth factor
(EGF), neuregulins, and transforming growth factor-α (TGF-α) among others.
Upon ligand binding, ErbB receptors undergo a conformational rearrangement
from a closed/tethered state to an open/extended conformation which exposes
regions necessary for receptor dimerization. This promotes homodimerization
and heterodimerization of the receptors. While HER2 cannot directly bind
ligands, it is preferentially recruited as a partner in heterodimers when these
ligands are bound to other ErbB family members, due to the fact that HER2
always exists in an open/extended, active conformation.
Unique patterns of C-terminal autophosphorylation then induce and dictate
specific interactions with cytoplasmic signal transduction partners, including
GRB2, Src, Shc, and p85, specific to each ErbB receptor. These events then in
turn promote a wide variety of cellular processes including, but not limited to,
proliferation, motility, and escape from apoptosis. HER2’s unique ability to
dimerize without ligand binding allows it to cause signaling pathway
dysregulation when HER2 is amplified/overexpressed.
The main downstream signaling pathways activated by HER2 and ErbB
receptors are the MAP Kinase and the PI3K/AKT pathways. The MAP Kinase
pathway is activated by ErbB receptors when the GRB2 adapter protein is
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recruited directly to phosphorylated C-terminal tyrosine sites or indirectly by
binding Src homology 2-containing (Shc). GRB2-Son of sevenless (Sos)
complexes form and recruit Ras, leading to signal transduction through the rest
of the MAP Kinase pathway to promote cellular proliferation, angiogenesis,
differentiation, and migration.
ErbB receptors can activate the PI3K/AKT pathway through direct
recruitment of the p85 regulatory subunit of PI3K to phosphorylated tyrosine
residues, which leads to activation of the p110α catalytic subunit of PI3K.
Additionally, GRB2 can interact with ErbB receptors and activate Ras, which then
activates p110α mediated signaling. Once activated, PI3K phosphorylated
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
trisphophate (PIP3). PIP3 in turn binds to the pleckstrin homology domain of
AKT. Then, phosphatidylinositol-dependent kinase 1 (PDK1) phosphorylates and
activates AKT. Activated AKT phosphorylates many downstream signaling
proteins associated with cellular survival, growth, proliferation, and angiogenesis.
HER2/HER3 dimers are the most potent activators of PI3K/AKT signaling. This is
due to the strong tyrosine kinase activity of HER2, while HER3 has 6 p85 binding
sites in its kinase domain to promote PI3K/Akt pathway activation (20). In
addition to the MAP Kinase and PI3K/Akt pathways, ErbB receptors can also
activate JAK/STAT, Src, and WNT signaling pathways (7,20).
Clinical importance of HER2 in breast cancer
In addition to their key role in normal cellular growth and maintenance, the
dysregulation of ErbB receptors has been extensively implicated in the
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development of numerous cancers. In a landmark study, Slamon et al. found that
HER2 is amplified in over 20% of breast cancers (26). HER2 is overexpressed in
the majority of cases of gene amplification and can also be overexpressed in the
absence of clear HER2 amplification. HER2 amplification/overexpression is
associated with decreased survival and time to relapse in breast cancer. It has
also been demonstrated that the growth of HER2-amplified/overexpressed
primary breast tumors as well as pulmonary metastases require the continuous
expression of HER2 to drive tumor growth (27). In addition to breast cancer,
HER2 amplification and overexpression has been described in other cancer
types, including ovarian, gastric, endometrial and lung cancer, where it is also an
indicator of poor prognosis (7,8,20).
With the identification of HER2 as a major driver in breast and other
cancers, it has become a prime target in the development of cancer therapies.
Two major classes of drugs targeting HER2, antibodies and tyrosine kinase
inhibitor, are currently in clinical use for the treatment of HER2-
amplified/overexpressed cancers. Antibodies, including the humanized
monoclonal antibody trastuzumab, can bind to the extracellular domain of HER2
and downregulate HER2 signaling through a complex variety of mechanisms. For
example, trastuzumab can inhibit receptor homo or heterodimerization, remove
HER2 receptors from the cell surface through endocytic internalization and
degradation, and promote an immunological response against the tumor cells by
activating a process known as antibody-dependent cellular cytotoxicity (ADCC)
when bound to a tumor cell (19,20).
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A number of small molecule inhibitors targeting HER2 are FDA approved
or in development. These include lapatinib, an EGFR/HER2 targeted reversible
tyrosine kinase inhibitor which competitively binds to the ATP-binding pocket of
the receptor kinase domain and neratinib, which is an irreversible dual
EGFR/HER2 inhibitor (20). These small molecules potently disrupt HER2
signaling, leading to inhibition of the MAP Kinase and PI3K/AKT pathways.
Interestingly, lapatinib has been shown to provide a clinical benefit in patients
with HER2-amplified/overexpressed cancers that have progressed after
treatment with trastuzumab (28). The successful use of these targeted therapies
in cancer patients has further demonstrated the importance of targeting HER2 as
a driver of tumorigenesis, however, many patients quickly develop resistance to
HER2 targeted therapies through a variety of mechanisms, including activating
mutations in the PI3K/AKT and MAP Kinase pathways (8,19,20).
Identification of HER2 missense mutations in human cancers
Large scale cancer genome sequencing efforts have provided a way to
identify low frequency mutations that may play important roles in the
development of cancer. A number of these studies have found recurrent
mutations in HER2 in human cancers including breast, stomach, bladder, and
lung cancers (10,11,29). In breast cancer, these mutations are most often found
in patients as single copies without amplification/overexpression of HER2 (HER2-
“negative” breast cancers) though HER2 protein expression is often still present
in these tumors. While other methods of mutational activation, including kinase
domain insertions and deletions of the extracellular domain, have been described
9
to activate HER2, the diversity and low frequencies of individual somatic
missense mutations have made it more difficult to fully characterize their potential
oncogenic effects (19).
Prior studies of HER2 missense mutations have utilized overexpression of
mutant HER2 cDNAs to investigate the effects of HER2 missense mutations in
human cells. These studies have implicated a number of these mutations as
potently activating and oncogenic (10,12,30-32). Notably, the V777L kinase
domain mutation was described to increase HER2 kinase activity, activate MAP
Kinase signaling, and increase invasiveness in three-dimensional culture,
anchorage independent growth in soft agar, and tumor growth as xenografts in
vivo when overexpressed in MCF-10A and MCF7 cells. The HER2 targeted
drugs lapatinib and neratinib inhibited the signaling and transformed phenotypes
imparted by the V777L mutation. Other missense mutations, including the
extracellular domain mutations G309A and S310F increase reduction sensitive
covalent dimerization and receptor activation when overexpressed. The G309A
and S310F mutations also increased features of transformation and were found
to respond to treatment with trastuzumab in overexpression studies (10,30).
Additionally, one missense mutation, L755S, has been associated with
biochemical signaling and proliferative resistance to lapatinib when
overexpressed, potentially due to steric interference of the binding site for small
molecule kinase inhibitors (10,33,34).
Single copy knock in models in the study of mutant oncogenes
10
Past studies comparing overexpression of a mutant cDNA to single
nucleotide knock in of mutant oncogenes have shown dramatic differences in
signaling and transformed phenotypes (35-37). In one example, knock in of the
mutant EGFR delE746-A750 allele into MCF-10A cells recapitulated biochemical
signaling phenotypes seen in overexpression models, but did not promote the
transformed phenotype of anchorage independent colony formation in soft agar
in MCF-10A cells that occurred with overexpression (37). Furthermore,
differences in phenotypes between overexpression and single copy knock in
models of mutant oncogenes have been reported in the study of genes including
AKT1 and KRAS (35,36).
In addition to recapitulating endogenous expression levels, another
important example to consider in modeling mutant oncogenes in the genetic
context in which these mutations exist. For example, it was shown that KRAS
G12V mutations as single copies have relatively little effect in breast epithelial
cells, but have a profound effect on cancerous phenotypes and tumorigenicity
when coupled with a PIK3CA oncogenic hotspot mutation (38). Given these
caveats to the overexpression of mutant oncogenes, we used two HER2 non-
amplified human breast epithelial cell lines to create an isogenic panel of HER2
missense knock in mutants. To our knowledge, this represents the first study of
the effects of single copy HER2 mutations under endogenous gene expression





The non-transformed human epithelial cell line MCF-10A and its
derivatives were maintained in DMEM/F12 (1:1) supplemented with 5% horse
serum (Life Technologies, Carlsbad, CA), 20 ng/ml EGF (Sigma-Aldrich, St.
Louis, MO), 10 µg/ml insulin (Life Technologies), 0.5 µg/ml hydrocortisone
(Sigma-Aldrich), and 0.1 µg/ml cholera toxin (Sigma-Aldrich), and 1% Penicillin-
Streptomycin (Life Technologies). MCF-10A cell lines with a PIK3CA E545K
mutation were maintained in this same media without EGF supplementation. For
assays using MCF-10A and its derivatives, DMEM:F12 (1:1) media containing
1% charcoal dextran stripped FBS (Life Technologies) with insulin,
hydrocortisone, cholera toxin and without EGF, with 0.2ng/mL, or with 20ng/mL
EGF, was used as indicated.
12
The MCF7 cell line and its derivatives were maintained in DMEM media
with 5% fetal bovine serum (Life Technologies) and 1% Penicillin-Streptomycin
(Life Technologies). For assays with MCF7 and its derivatives, DMEM:F12 (1:1)
media without phenol red was supplemented with 0.5% charcoal dextran stripped
FBS (serum starved) or DMEM media with 5% FBS (serum supplemented) was
used as indicated unless otherwise noted. MCF-10A parental, MCF7 parental,
and HEK-293T cells were purchased from ATCC (Manassas, VA). MCF-10A +
E545K cells were derived in a previous study (39). The MCF7 corrected cell line
was also generated in a previous study (40). MCF-10A HER2 wild type, G309A,
L755S, and V777L overexpression cell lines were generated in a previous study
(10). Parental cell lines were authenticated via short tandem repeat profiling
analysis at the Johns Hopkins Genetic Resources Core Facility. A complete list
of cell lines generated and used in this study can be found in Table 1.
Gene targeting and generation of HER2 missense mutation cell lines:
Gene targeting was carried out using recombinant AAV vectors as
previously described (39). Gene targeting of HER2 was carried out using one of
three distinct recombinant AAV vectors (Figure 1A). Gene targeting was
performed as previously described (Figure 1B) (41). AAV vectors were produced
by ligating wild type homology arms generated by PCR into an AAV plasmid
backbone (Agilent, La Jolla, CA). Site-directed mutagenesis by overlap extension
PCR with subsequent cloning into the parental AAV plasmid backbone was used
to generate a targeting construct for each HER2 mutation that was studied (42).
Infectious virus was prepared by co-transfecting HEK-293T cells with pHelper,
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pRC (Agilent) and the respective HER2 mutation carrying rAAV targeting
plasmid. Approximately 106 cells were used for each viral infection, and a sib
selection strategy was employed as previously described (43). Targeted
neomycin resistant clones were isolated and cells were then exposed to Cre-
expressing recombinant adenovirus to remove the neomycin cassette as
previously described (41). All clones were subjected to confirmation by Sanger
sequencing of genomic DNA and cDNA to ensure each clone harbored the
intended HER2 mutation as single expressed copies (Figure 2). Single-stranded
cDNA was generated using First Strand cDNA Synthesis Kit (Amersham
Biosciences, Piscataway, NJ). At least two clones were isolated for each
mutation in each parental background. In addition, AAV gene targeting using wild
type HER2 constructs to create targeted wild type controls for each locus. Primer
sequences for homology arm construction, mutagenesis, pre-Cre PCR
screening, post-Cre PCR screening, genomic DNA sequencing, and cDNA
sequencing can be found in Table 2 and Table 3.
Overexpression of HER2, HER3, and PIK3CA cDNAs in human cells:
HEK-293T cells were transfected using the Fugene 6 system (Promega,
Fitchburg, WI). pCFG5 plasmids containing wild type, G309A, L755S, or V777L
HER2 cDNAs, and LXSN plasmids containing wild type or E545K mutant
PIK3CA were derived in previous studies (10,38). A wild type HER3 expression
vector was created by subcloning HER3 cDNA from the pCMV6-XL4-ERBB3
plasmid (SC118918; Origene, Rockville, MD) into a pIRES-neo3 backbone.
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Lysates from HEK-293T cells harvested approximately 48 hours after
transfection with the indicated plasmids.
Cell proliferation assays:
Exponentially growing cells were washed twice with HBSS and seeded in
the indicated media. Cells were seeded at a density of 2x104 cells per well of a 6-
well tissue culture dish on day 0. Medium was changed every third day. Cells
were harvested on the indicated days and were counted using a Beckman
Coulter counter and relative proliferation was calculated using the average
proliferation of the first time point for each cell line as a reference. Results for
targeted wild type and HER2 mutant cell lines represent data from two or more
clones unless otherwise indicated. For some assays, cells were also fixed and
stained with 3.7% formaldehyde containing 0.2% crystal violet (Sigma-Aldrich).
Drug inhibitor assays:
Lapatinib, neratinib, and BYL-719 were obtained from Selleck (Houston,
TX) and were dissolved in dimethyl sulfoxide (DMSO). Trastuzumab was
obtained from the Johns Hopkins Research Pharmacy (Baltimore, MD) and was
dissolved in bacteriostatic water. 1-2x103 cells per well were plated into 96-well
plates on day 0. MCF-10A derivatives were grown in assay media containing
20ng/µL EGF, MCF-10A derivatives with PIK3CA E545K mutation were grown in
assay media without EGF, while MCF7 and MCF7 corrected derivatives were
grown in assay media containing 5% FBS. On day 1, media was changed to
contain the indicated concentration of drug or appropriate vehicle control. Alamar
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blue (Life Technologies) was used to determine cell proliferation on day 6
according to the manufacturer’s instructions. IC50 values were calculated using
the log(inhibitor) vs. response – variable slope (four parameters) nonlinear
regression function in Graphpad Prism 5 (GraphPad Software, La Jolla, CA).
Experiments were performed in sextuplet for each concentration of drug for each
cell line.
Colony formation assay in semisolid medium:
5x103 exponentially growing cells were cast in 3 mL of top-later medium
comprised of assay media with 20ng/mL EGF for MCF-10A derivatives or 5%
FBS for MCF7 derivatives and 0.4% UltraPure Agarose (Life Technologies)
poured on top of a 2mL bottom layer containing 0.6% agarose in 6-well tissue
culture plates. Media was refreshed once a week. For assays with inhibitors or
DMSO vehicle controls (0.5%), compounds were added at the indicated
concentrations the day after plating. After 4 weeks of incubation, the colonies
were stained with crystal violet and visually inspected for proliferating colonies.
One to three fields per well were counted to for each well per experiment with
wells plated in at least duplicate. Photographs were taken with a Nikon SMZ
1500 stereoscopic zoom microscope.
Acinar morphogenesis assay:
Morphogenesis assays were conducted in growth factor reduced Matrigel
(BD Biosciences, San Jose, CA) as previously described (44). For acinar
morphogenesis assays in the presence of inhibitors or DMSO vehicle controls
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(0.5%), compounds were added at the indicated and media was changed every
four days. Photographs were taken under phase contrast microscopy (Nikon)
after 12 days of incubation.
Immunoblotting:
Cells were washed twice and seeded in the indicated media. After 48
hours, cells were harvested for protein lysates, and immunoblotting was
conducted as previously described (35). Briefly, whole-cell protein extracts
prepared in Laemmli sample buffer were resolved by SDS-Page using NuPAGE
gels (Invitrogen), transferred to polyvinylidene diflouride (PVDF) membranes
(Invitrogen), and probed with primary antibody followed by incubation with
horseradish peroxidase-conjugated secondary antibodies. The primary
antibodies used in this study include anti-phospho ErbB-2/HER-2 (Tyr1248)
rabbit antibody (06-229; Millipore, Billerica, MA), anti-HER2/ErbB2 rabbit
antibody (2242; Cell Signaling Technology, Danvers, MA), anti-phospho-p44/p42
MAP kinase (Thr 202/Tyr 204) rabbit antibody (4370; Cell Signaling Technology),
anti-p44/p42 MAP kinase rabbit antibody (9102; Cell Signaling Technology), anti-
phospho-EGF receptor (Tyr 1068) rabbit antibody (3777; Cell Signaling
Technology), anti-EGF receptor rabbit antibody (4267; Cell Signaling
Technology), anti-phospho AKT (Ser 473) rabbit antibody (9271; Cell Signaling
Technology), anti-AKT rabbit antibody (9272; Cell Signaling Technology), anti-
phospho p90RSK rabbit antibody (9341; Cell Signaling Technology), anti-
p90RSK rabbit antibody (9333; Cell Signaling Technology), anti-phospho
HER3/ErbB3 (Tyr 1289) rabbit antibody (4791; Cell Signaling Technology), anti-
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HER3/ErbB3 rabbit antibody (4754; Cell Signaling Technology), anti-PI3 Kinase
p85 (19H8) (4257; Cell Signaling Technology), anti-phospho p70 S6 Kinase
(Thr389) (9205; Cell Signaling Technology), anti-p70 S6 Kinase (9202; Cell
Signaling Technology), and anti-GAPDH rabbit antibody (5174; Cell Signaling
Technology).
Immunoprecipitation:
Cells were grown in serum starved media conditions and were then
washed with ice-cold PBS, scraped, and lysed on ice in lysis buffer containing
1% Triton X-100, 10% glycerol, 100mM NaCl, 50mM Hepes (pH 7.2), 10mM NaF
(all from Sigma-Aldrich), 10mM Na3VO4 (New England Biosciences, Ipswich,
MA), and Roche minitab cOmplete protease inhibitor with EDTA (Roche, Basel,
Switzerland). Lysates were cleared by centrifugation at 14,000 rpm for ten
minutes at 4ºC. Protein concentration was measured using the BCA protein
assay reagent (Pierce, Rockford, IL). Immunoprecipitation was performed by
incubating 1mg of protein extract with 1µg of anti-HER3 antibody (Millipore 05-
390) overnight at 4ºC. Lysates were then incubated with Dynabeads Protein G for
immunoprecipitation (Life Technologies) for 4 hours at 4ºC. Beads were then
washed with lysis buffer and boiled for 5 minutes in 2x loading buffer before
being subjected to SDS/PAGE.
Scratch wound healing assays:
Cells were plated in 6-well cell culture plates and grown to near confluent
monolayers. Scratch wounds were introduced in a cross pattern with a 200 µL
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pipette tip. For assays with inhibitors, compounds were added at the indicated
concentrations after the scratch wound was introduced. Phase contrast images
were taken to the left and/or right of the center of the cross wound after media
was replaced and were followed over time. Initial wound area and area after
indicated time points were calculated using the Scratch Assay Analyzer tool in
the MiToBo plugin for ImageJ 2.0 with σ = 2 and entropy filter size = 25. The
fraction of wound closure was calculated by dividing the final wound area by the
initial wound area and subtracting the resulting value from 1. For MCF-10A cell
lines, the assay was performed in media supplemented with 20ng/mL EGF. For
MCF-10A cell lines with a PIK3CA E545K mutation, EGF free media conditions
were used. MCF7 and MCF7 corrected derivatives were assayed in 10% serum
supplemented media.
Microchannel migration assays:
Standard photolithography and replica molding were used to create the
polydimethylsiloxane (PDMS) microfluidic device designed for studying cell
migration, as previously described (45-48). Arrays of microchannels that are
200µm long, 10µm tall, and have widths of 50µm, 20µm, 10µm, 6µm, or 3µm
were connected at one end to a channel for cell seeding and at the other end to a
channel containing a chemoattractant. 6mm diameter inlets and outlets were
punched in the PDMS device to allow the addition of media and cells. The PDMS
device and a glass coverslip were plasma cleaned, and the PDMS device was
adhered to the glass surface. Collagen Type I (BD Biosciences) at 20µg/mL in
phosphate buffered saline (PBS) was absorbed for one hour at 37oC. Prior to the
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addition of cells, the collagen solution was aspirated and the device was washed
with PBS. 50,000 cells in 50µL of serum-free media were added to the cell inlet
of the microfluidic device. Cells align at the entrance to microchannels and a
chemotactic gradient is established along the microchannels. For MCF-10A
derivatives, a gradient of media containing no to 5% horse serum was
established, while for MCF7, a gradient of media containing no to 10% FBS was
used. Cell migration was observed by time-lapse microscopy at 10 min intervals
for 12 hours or more. In each frame, the xy position of a cell was defined by the
central cell body. Cellular velocity, displacement, and distance traveled were
calculated by a custom MATLAB program. Data are representative of ≥30
tracked cells per cell line and at least three independent experiments.
Flow cytometry and extracellular staining:
1x106 cells were treated with Human TruStain FcX Fc receptor blocking
solution (BioLegend, San Diego, CA) before staining. Data were collected using
a FACSCalibur II and analyzed using FACSComp software (BD Biosciences).
Gates and quadrants were set based on isotype control staining. The following
fluorochrome labeled antibodies were used: APC anti-human CD340
(erbB2/HER-2) (324407; BioLegend), PE anti-human erbB3/HER-3 antibody
(324705; BioLegend), APC mouse IgG1, κ isotype control (FC) antibody




For each group, at least five 8- to 10-week-old female athymic nude mice
(Harlan Laboratories, Indianapolis, IN) with or without estrogen pellet
supplementation as noted were injected subcutaneously in either flank with 200
µl mixture containing 2x106 cells in 20% PBS and 80% growth factor reduced
Matrigel (BD Biosciences). Tumor volumes were analyzed weekly and calculated
by multiplying length, width, and height for each individual tumor.
For tail vein injection assays, 1x105 cells in 200 µl of PBS were injected
into the tail vein of 8- to 10-week-old female athymic nude mice. After 5 weeks,
animals were euthanized and their lungs were excised and fixed in 10% formalin
and embedded in paraffin, cut into sections and stained with hematoxylin and
eosin. Lungs were examined grossly, and five stained sections were examined
for evidence of multicellular, proliferating disease per experimental group under a
phase contrast microscope.
All animal experiments were performed in accordance with institutional
and The National Institutes of Health Guide for the Care and Use of Laboratory
Animals guidelines
Statististics:
All statistical analyses were performed using GraphPad Prism 5 software
(GraphPad Software). Unpaired Student’s T tests, 1-way ANOVA, and 2-way
ANOVA tests were used to compare experimental groups to the appropriate
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control. Significance levels are indicated using one or more asterisks: P ≤ 0.05
(*), P ≤ 0.01 (**), and P ≤ 0.001 (***). Error bars represent ± SEM.
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3 Results
Targeted knock in of single copy, heterozygous HER2 missense mutations
in HER2 non-amplified human breast epithelial cell lines
In order to model HER2 missense mutations as found in human cancers,
we used adeno-associated virus (AAV)-mediated gene targeting to create an
isogenic panel of HER2 mutant knock in MCF-10A and MCF7 human breast
epithelial cells. These two cell lines do not overexpress or have amplification of
HER2, thus heterozygous knock in cell lines contain one wild type and one
mutant copy of HER2, and express HER2 protein at levels consistent with HER2
non-amplified tumors (Figure 1A) (49). Three AAV gene-targeting vectors were
used as backbone vectors to introduce each of seven previously reported
mutations into the extracellular or kinase domains of HER2 (Figure 1 and Table
4). Two heterozygous HER2 mutant clones were generated for each HER2
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mutation. We also generated wild type control clones using wild type AAV vector
backbones for both MCF-10A and MCF7. Cell lines were verified to have a single
integrated copy of the desired mutation and equivalent expression of the mutant
and wild type alleles using PCR and RT-PCR followed by Sanger sequencing
(Figure 2).
HER2 V777L mutation increases HER2 signaling pathway activation in non-
transformed MCF-10A cells
Overexpression studies have identified that HER2 mutations, including
G309A, S310F, L755S, V777L, and R896C activate HER2 signaling and promote
transformation. To assess whether these effects could be recapitulated in
genome edited clones, we initially performed western blotting analysis on our
MCF-10A isogenic panel. MCF-10A is a non-transformed human breast epithelial
cell line with a mostly diploid karyotype that requires EGF supplementation for
proliferation in culture (50). Using genome editing, we have demonstrated that
MCF-10A cells can be transformed by the introduction of oncogenic mutations
both in vitro and in vivo (38).
We found that MCF-10A HER2 V777L cells showed increases in
phosphorylation of HER2, EGFR, and ERK compared to control cell lines in
0.2ng/mL EGF (physiologic) (Figure 3) and EGF-free (Figure 4) conditions. No
difference in AKT phosphorylation was noted in gene targeted clones (Figure 3
and Figure 4) indicating that activation of the HER2 receptor by this mutation
preferentially activates ERK signaling. Interestingly, other HER2 mutations did
not consistently activate HER2 signaling in MCF-10A cells. These results
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demonstrate that HER2 mutations, even those occurring in the same domain of
the protein, have distinct effects on signaling pathway activation.
HER2 mutant MCF-10A cells do not exhibit oncogenic properties in vitro
Prior overexpression studies identified that HER2 mutations can lead to
transformative changes, including increases in anchorage independent growth
and aberrant morphology in three-dimensional culture, even without detectable
increases in HER2 phosphorylation (10,30). Therefore, we performed a series of
assays to identify transformed properties of our HER2 mutant cell line panel.
While parental MCF-10A cells require EGF supplementation, EGF
independence has been demonstrated to be a feature of transformation in MCF-
10A cells (39). However, HER2 mutations did not confer EGF independence
(Figure 5A), and there was little difference in proliferation rates between control
and HER2 mutant cells in assay media containing either 0.2ng/mL (physiologic)
or 20ng/mL (maintenance dose) EGF (Figure 5B-C).
We next tested the ability of HER2 mutations to promote anchorage
independent growth in MCF-10A cells. Knock in of HER2 V777L was not
sufficient for colony formation in soft agar, although MCF-10A cells that
overexpress HER2 V777L mutant cDNA formed robust colonies in soft agar as
previously reported (10) (Figure 6A). Anchorage independent growth in semisolid
medium was not observed in other MCF-10A HER2 mutant cell lines (Figure 6A).
Next, we examined acinar morphology of MCF-10A HER2 mutant knock in cells
in three-dimensional culture. All HER2 mutant knock in cell lines formed spherical
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structures with normal polarization similar to controls (Figure 6B). This was
distinct from phenotypes observed with overexpression of HER2 mutant cDNAs,
which led to larger, irregular, spiculated structures with abnormal protrusions
(Figure 6B).
HER2 V777L and L755S mutations increase HER2 pathway signaling
activation in MCF7 cells
While biochemical signaling differences were modest in MCF-10A HER2
knock in cell lines, we hypothesized that HER2 missense mutations may be
highly context dependent and require cooperating genetic alterations found in
cancer cells to promote additional transformative features. Therefore, we created
an isogenic panel of HER2 mutant MCF7 cell lines containing single copies of
HER2 mutations. The parental MCF7 cell line is derived from a metastatic pleural
effusion in a patient with ER-positive breast cancer and does not overexpress
HER2 protein. Two HER2 kinase domain mutations, L755S and V777L, and one
extracellular domain mutation, G309A, were chosen for genome editing in MCF7
cells since these mutations have been characterized via overexpression studies
to result in increased pathway activation, oncogenic phenotypes, and, in the case
of L755S, resistance to lapatinib (10,34). It should be noted that MCF7 contains
two copies of an activating E545K PIK3CA mutation and one wild type copy of
PIK3CA (40), a known oncogene involved in PI3 Kinase and MAP Kinase
pathway signaling (39).
We initially tested the effects of HER2 mutations in MCF7 cells by
examining signaling pathway activation. Consistent with the results in the MCF-
26
10A background, MCF7 HER2 V777L cells showed increases in phosphorylation
of HER2, EGFR, and ERK compared to parental MCF7 and control cells in
serum starved conditions (Figure 7A) and HER2 in serum supplemented media
(Figure 7B). Furthermore, the L755S mutation increased activation of HER2
signaling pathway proteins in MCF7 (Figure 7). In addition, MCF7 cells have
greater basal expression of HER3 than MCF-10A cells, and MCF7 HER2 V777L
and L755S cell lines exhibited an increase in HER3 phosphorylation (Figure 7).
Notably, AKT activation did not differ significantly among MCF7 parental, control,
and HER2 mutant cell lines. Despite this pathway activation, HER2 mutations did
not affect proliferation in MCF7 cells (Figure 7).
HER2 missense mutations cooperate with mutant PIK3CA for augmented
pathway activation in MCF7 cells
Since MCF7 HER2 L755S and V777L cells showed greater signaling
activation than their MCF-10A counterparts, we hypothesized that mutant
PIK3CA E545K in MCF7 may cooperate with HER2 mutations to increase
pathway activation and other transformed phenotypes. Numerous studies have
implicated PIK3CA mutations in transformation and activation of the PI3
Kinase/AKT pathway (39,51). To test this hypothesis, we used genome editing to
introduce the HER2 V777L mutation into MCF7 cells that had previously
undergone gene targeting to restore the PIK3CA alleles to wild type (referred to
as MCF7 corrected) (40). The resulting cells have three wild type copies of
PIK3CA and a heterozygous HER2 V777L mutation (referred to as MCF7
corrected + V777L) (Figure 2C).
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MCF7 corrected + V777L cells displayed slightly lower levels of
phosphorylated HER2, HER3, and ERK compared to MCF7 HER2 V777L cells,
but relatively more than both MCF7 and MCF7 corrected cells (Figure 8). These
results suggest that the HER2 V777L mutation activates the MAP Kinase
pathway in MCF7 cells and that mutant PIK3CA may augment this signaling,
similar to our past studies (39). Interestingly, both MCF7 corrected and MCF7
corrected + V777L cells had dramatically reduced AKT phosphorylation. While it
has been shown that the absence of PIK3CA mutations in MCF7 cells lowers
activation of the PI3 Kinase/AKT pathway (40), it was unexpected that isolated
activation of HER2 signaling via the V777L mutation did not lead to any
discernable increase in AKT phosphorylation. This result, along with the
concurrent increases in ERK phosphorylation, again suggests that V777L HER2
preferentially activates the MAP Kinase signaling pathway rather than the PI3
Kinase/AKT signaling pathway. MCF7 corrected and its derivatives also grew
similarly to each other, but more slowly than MCF7 parental cells in serum
starved conditions (Figures 7-9).
Acinar morphology and anchorage independent growth in MCF7 HER2
mutant cell lines
To determine any morphologic effects of HER2 mutations in MCF7 cells,
we conducted Matrigel assays. All cell lines appeared similar to parental and
control cells. When cells were seeded in Matrigel along with the EGFR/HER2
inhibitor lapatinib, there was little to no effect on the size or morphology of the
acini (Figure 10).
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We then performed soft agar colony formation assays to test the ability of
HER2 mutations to promote anchorage independent growth in MCF7 cells. While
MCF7 V777L clones showed a trend toward increased colony number, this was
modest relative to controls. Similarly, MCF7 HER2 G309A and L755S did not
differ significantly from controls (Figure 11). Treatment with lapatinib had a strong
inhibitory effect on colony size and formation in all tested cell lines, though there
were no significant differences between HER2 knock in clones and controls
(Figure 11A). MCF7 corrected + V777L mutant cells did not exhibit transformed
phenotypes in in vitro assays compared to controls (Figure 11B and Figure 12).
These data suggest that while PIK3CA mutations may cooperate with HER2
mutations to accentuate signaling activation in MCF7 cells, this cooperativity is
not sufficient to increase anchorage independent growth or promote abnormal
acinar morphology.
Cooperativity between HER2 and PIK3CA mutations leads to increased
signaling activation in MCF-10A cells
Since the effects of HER2 missense mutations as single copies were
greater in MCF7 cells compared to MCF7 corrected cells, we wanted to confirm
that activating E545K PIK3CA mutations in MCF7 HER2 mutant cells contributed
to the observed effects. Therefore, we created PIK3CA and HER2 double mutant
cell lines by knock in of the PIK3CA E545K mutation into our MCF-10A HER2
L755S and V777L cell lines. These resultant double knock in cell lines (referred
to as L755S DKI and V777L DKI) are heterozygous for their respective HER2
mutation and for the PIK3CA E545K mutation.
29
We first analyzed activated signaling pathways via western blot in DKI and
control cell lines in media with 0.2ng/mL or without EGF. It has been previously
demonstrated that MCF-10A cells with knock in of PIK3CA E545K (referred to as
MCF-10A + E545K) activated both the PI3 Kinase and MAP Kinase pathways
compared to MCF-10A parental cells (38,39). MCF-10A HER2 V777L cells had
increased levels of HER2 phosphorylation compared to MCF-10A + E545K cells
but had similar levels of ERK phosphorylation (Figure 13 and Figure 14).
Additionally, both L755S DKI and V777L DKI cell lines showed increases in
HER2, EGFR, and ERK phosphorylation compared to MCF-10A + E545K cells
and in ERK activation compared to their respective single HER2 mutation knock
in cell lines in media supplemented with 0.2ng/mL EGF (Figure 13A). Differences
in EGFR phosphorylation were less apparent in EGF free media conditions
(Figure 14A). The DKI cell lines also showed slight increases in AKT
phosphorylation compared to PIK3CA single knock in cells in EGF free
conditions (Figure 14A), but not in the presence of 0.2ng/mL EGF (Figure 13A).
Interestingly, there was an increase in the ratio of phosphorylated HER2 to total
HER2 in L755S DKI and V777L DKI cells compared to their respective single
knock in cell lines in EGF free conditions, which was also present in both L755S
DKI and one of two V777L DKI cell lines in 0.2ng/mL EGF conditions (Figure 13B
and Figure 14B). Although HER2 is classically considered upstream of PI3K,
these results indicate that under certain conditions interactions between mutant
PIK3CA and mutant HER2 may lead to “rewiring” and dysregulation of signaling
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pathways. Similar pathway dysregulation has been reported in other studies
(39,52,53).
Because PIK3CA mutations have been shown to confer EGF-independent
growth properties to MCF-10A cells, we tested if HER2 mutations could augment
this phenotype. L755S and V777L DKI cells proliferate in EGF-free media, but
this growth was not increased compared to MCF-10A + E545K cells (Figure 15).
Furthermore, the combination of HER2 and PIK3CA mutations did not confer
anchorage independent growth to MCF-10A cells, and proliferating colonies were
not observed in soft agar assays (Figure 16A). We next seeded the L755S and
V777L DKI cell lines in Matrigel to examine their morphology. Both L755S DKI
and V777L DKI cells grew with a morphology similar to controls that was not
affected by treatment with lapatinib (Figure 16B). Taken together, our results
suggest that while signaling pathway activation was increased in DKI cell lines,
this is not sufficient to promote transformation in these assays.
HER2 V777L and PIK3CA E545K double mutant cell lines have increased
migratory capacity in vitro
Since HER2 overexpression and activation of HER2 signaling have been
described to lead to increases in cell migration, we next tested the migratory
capacity of HER2 mutant cell lines in scratch wound healing and chemotactic
microchannel migration assays. In scratch wound experiments, MCF-10A V777L
DKI cells exhibited significantly increased wound closure compared to both MCF-
10A + E545K and L755S DKI cell lines. Treatment with lapatinib significantly
reduced the migration of V777L DKI cells (Figure 17). L755S DKI cells exhibited
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slower wound closure than the MCF-10A + E545K cells, indicating that the ability
to promote migration may be unique to the V777L mutation. Single V777L knock
in cells did not migrate more quickly than MCF-10A parental or control cells
(Figure 19). In accord with these results, the MCF7 HER2 V777L cell line also
showed an increase in wound closure compared to parental control, which was
decreased with lapatinib treatment and not present in MCF7 corrected + V777L
cells (Figure 18 and Figure 19).
We next examined the migratory capacity of cells with and without HER2
V777L mutation in collagen-I coated microchannels using a microfluidic device
constructed of polydimethylsiloxane (PDMS) (45-48). This device allows for the
characterization of single cell migration, rather than the collective migration
observed during wound closure. Individual cells migrate up a chemotactic
gradient inside 10µm tall channels of prescribed widths. Because all tested cells
do not efficiently migrate through narrow channels (10µm wide or less) we
focused our quantitative analysis on cells migrating in 50µm and 20µm wide
channels (46).
MCF-10A V777L DKI cells displayed higher migration velocity and
persistence (defined as the ratio of net cell displacement to total distance
traveled) inside the 50µm channels compared to MCF-10A + E545K cells (Figure
20A). Similarly, MCF7 V777L cells exhibited an increased migratory propensity
compared to parental MCF7 (Figure 20B). Although both MCF-10A V777L DKI
and MCF7 V777L migrated faster than their corresponding controls in 20µm wide
channels, no significant difference was detected in persistence (Figure 20). MCF-
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10A cells with a HER2 V777L mutation, but not a PIK3CA E545K mutation did
not migrate more quickly than either parental MCF-10A or MCF-10A + E545K
cells (Figure 21). Taken together, these studies demonstrate that HER2 V777L
cooperates with the PIK3CA E545K to confer increased migratory potential in
breast epithelial cells.
HER2 missense mutations do not lead to increased tumor growth or
invasion in vivo
The ability of HER2 mutations to increase tumor formation and xenograft
growth was tested (Figure 22A). MCF7 HER2 mutant cell lines did not differ
significantly in their growth compared to controls. Additionally, HER2 mutations
did not confer the ability for MCF7 cells to grow without estrogen
supplementation in nude mice (Figure 22B). While MCF-10A + E545K cells do
not form tumors, prior studies have shown that MCF-10A cells with double knock
in of PIK3CA and KRAS mutations can cooperate to promote tumor formation.
Since we observed cooperativity between PIK3CA and HER2 mutations in MCF-
10A cells, we also tested the ability of L755S and V777L DKI cell lines to form
tumors. However, these cell lines did not form tumors in vivo after twelve weeks
(Table 5).
Our in vitro experiments revealed an increased migratory potential for
HER2 V777L DKI cells, therefore we performed a tail vein injection assay to test
the in vivo invasiveness of MCF7 HER2 mutant cell lines. MCF7 is a cell line with
low metastatic capability and infrequently forms disease sites in the lungs after
injection into the bloodstream through the tail vein (54,55). HER2 mutant cell
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lines did not form any sites of proliferating, multicellular disease in the lungs of
nude mice as determined by gross and microscopic inspection (Figure 23).
Overall, these results differ from the predicted effects from overexpression
experiments of V777L and G309A mutations in MCF7 cells, which formed tumors
that grew significantly faster than wild type HER2 overexpression (10). These
results suggest that knock in models of HER2 mutations may reveal different
roles for these mutations in tumor growth when expressed from their endogenous
loci and that additional oncogenic alterations are required to impart invasive
phenotypes to HER2/PIK3CA mutant cells.
HER2 and PIK3CA mutations cooperate to increase interaction between
HER3 and p85
We examined potential interactions in the HER2 signaling pathway that
may be responsible for the cooperative effects of HER2 and PIK3CA mutations.
Previous work has shown that overexpression of HER2 in cells with PIK3CA
mutations enhance HER2-mediated signaling through HER3 and p85 (56). Using
the MCF7 cell line panel, we performed immunoprecipitation assays to examine
the effect of HER2 and PIK3CA mutations on HER3/p85 dimerization. MCF7
HER2 L755S and V777L cells showed an increase in HER3-p85 interaction
relative to HER2 and PIK3CA wild type cells (Figure 24). Because HER3 levels
are significantly lower in MCF-10A cells, this precluded our ability to perform
immunoprecipitation assays in our MCF-10A cell line panel. Therefore, we
overexpressed mutant or wild type HER2 and PIK3CA, along with wild type
HER3 in HEK293T cells to examine the consequences of their interactions in
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another cellular background. Similar to our results with MCF7 cells, the presence
of HER3-p85 dimers increased in cells transfected with both V777L HER2 and
E545K PIK3CA compared to wild type controls (Figure 25). This increase in
HER3-p85 interaction in V777L mutant cells may represent a potential signaling
pathway “rewiring” leading to increased MAP Kinase activation via HER3/PI3
Kinase interaction as we have previously described (57). These results suggest
that the V777L HER2 missense mutation in combination with PIK3CA mutations
increase the formation of HER3-p85 dimers and may be a potential mechanism
of increased MAP Kinase pathway signaling.
HER2 mutations and proliferative response to HER2 targeted therapies
Given that overexpression models of HER2 mutations revealed differential
sensitivities to HER2 targeted drugs, we measured the IC50 values of two
HER2/EGFR tyrosine kinase inhibitors, lapatinib and neratinib, on our isogenic
HER2 knock in cell line panel (Supplemental Tables 3-4 and Supplemental
Figure 8) (10,34).
For MCF-10A cells, ~650-1000 nM lapatinib was necessary to inhibit cell
proliferation for cells regardless of HER2 and/or PIK3CA mutation status (Table
6, Figures 26A and 27A). While MCF7 cells were relatively insensitive to
lapatinib, HER2 mutations again did not alter the response to lapatinib (Table 6
and Figures 28A and 29A). Interestingly, cells harboring a HER2 L755S mutation
did not exhibit resistance to lapatinib in terms of proliferation or biochemical
pathway activation (Table 7 and Figure 31). Similar to the results of lapatinib
treatment, HER2 mutations did not predict for substantial sensitivity or resistance
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to neratinib in our cell line models. However, neratinib was slightly more potent in
L755S DKI cell lines compared to control (Table 7 and Figure 27B). This
sensitivity was not found in MCF-10A HER2 L755S or MCF7 HER2 L755S
backgrounds (Table 7 and Figures 26B and 28B). Moreover, all cell lines were
relatively insensitive to trastuzumab at doses up to 100µg/mL, perhaps due to the
poor anti-signaling effect and complex mechanism of action of trastuzumab (data
not shown) (20). Additionally, cell lines with both a PIK3CA and a HER2 mutation
were not more sensitive to the PI3K p110α specific inhibitor BYL-719 than cells
with a single PIK3CA mutation. As expected, cells without a PIK3CA mutation










































HER2 mutations in non-amplified/non-overexpressed breast cancers
represent a phenomenon that can potentially be exploited therapeutically. While
previous overexpression studies of mutant HER2 cDNAs have suggested that a
number of HER2 mutations are activating and promote transformation, our study
found only the V777L mutation to be of functional significance. Perhaps most
interesting, the effects of the HER2 V777L mutation appear to be accentuated by
a cooperating mutation, in this case the PIK3CA E545K hotspot mutation.
Consistently across two different human breast cell line models, HER2 V777L
combined with PIK3CA E545K imparted features of increased signaling pathway
activation and migration as noted by changes in western blotting, scratch wound
healing, and microchannel migration assays. Notably, the HER2 V777L kinase
domain mutation led to an increased interaction between p85 and HER3 in the
presence of a PIK3CA E545K mutation. These results suggest that HER2
missense mutations require additional genetic alterations to promote features of
transformation. In addition, the HER2 mutation L755S, which previous
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overexpression studies have shown imparts resistance to lapatinib (10,33,34,58)
did not show obvious resistance phenotypes in our genome edited cell lines. It is
conceivable that endogenous expression of L755S mutant HER2 in our models
may not be sufficient to produce resistance to lapatinib due to lower levels of the
mutant protein. This finding may be of clinical importance, since patients that do
not have amplification/overexpression or high expression of L755S mutant HER2
may still be sensitive to lapatinib, an FDA approved therapy for HER2-amplified
breast cancers.
Targeting HER2 mutations in HER2 negative disease is a potential
avenue to apply already FDA approved therapies to a new patient population.
Indeed, trials are ongoing to test this hypothesis, but given the rarity and variety
of HER2 mutations, such trials may be underpowered to definitively address this
question. Since the majority of HER2 mutations in clinical samples are not
amplified or overexpressed, we evaluated seven previously reported HER2
mutations using somatic cell gene targeting to gain insight into this issue.
However, we recognize that our models are limited in complexity compared to
what is present in patients’ tumors, where interacting factors including the
immune system, varying protein expression levels, and tumor microenvironment
can influence response to targeted therapies. Nonetheless, our isogenic cell line
models of HER2 mutations provide useful tools for understanding the functional
consequences of HER2 mutations in isolation and in combination with other
oncogenes, as well as testing responses to targeted therapies.
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Our study illustrates that different HER2 mutations impart distinct or
absent phenotypes depending on the individual mutation and the presence of
other genetic alterations in oncogenes. This is perhaps not surprising given
recent work demonstrating similar findings for AKT1 and HER3 mutations
(59,60). This has implications for predicting response to targeted therapies. For
example, in our study, HER2 mutations did not overtly promote cell proliferation.
Therefore it may be expected that HER2 targeted therapies would not show
differential sensitivity to cells harboring these mutations in terms of reducing cell
number in standard growth assays. On the other hand, the V777L HER2
mutation in the appropriate context (e.g. oncogenic PIK3CA mutations) led to an
increase in cellular migration, potentially resulting in increased metastatic
potential that was affected by the HER2 inhibitor lapatinib. HER2-directed
therapies in this regard may be capable of ablating this phenotype in patients,
and therefore could possibly afford clinical benefit.
The variable effects of individual HER2 mutations coupled with the
requisite need for oncogene cooperativity may prove challenging for the use of
HER2 mutation status to guide therapy for breast cancer patients. Our studies
have implicated oncogenic mutant PIK3CA as a potential partner to HER2
mutations, and, indeed, HER2 kinase domain mutations and PIK3CA mutations
have been reported concurrently in breast cancer sequencing efforts (29). We
tested the effects of PIK3CA mutations in conjunction with HER2 mutations due
to their close relationship as members of the same signaling pathway however, it
is likely that there are other genes in the MAP Kinase and PI3 Kinase pathways,
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which when mutated may cooperate with HER2 missense mutations to impart
transformative effects on cells. Indeed, the relatively low frequency of HER2
missense mutations may be explained by a need for certain concurrent
oncogenic mutations to achieve a selective advantage in HER2 mutant tumors.
Additionally, it may explain why many HER2 mutations in our isogenic models did
not have a detectable phenotype even though they are recurrently found in
human cancers. Further work in this regard is ongoing and may help elucidate
whether mechanisms of cooperativity are shared or unique among altered
oncogenes and tumor suppressors and HER2 mutations.
In conclusion, using an isogenic panel of non-amplified/non-
overexpressed HER2 mutant cell lines, we have determined that the majority of
HER2 mutations alone are not sufficient to promote transformative phenotypes in
breast cell lines. However, HER2 kinase domain mutations, notably V777L, can
exhibit cooperativity with the activating PIK3CA E545K mutation. Cells with both
HER2 V777L and PIK3CA E545K mutations exhibited key features of
transformation in vitro, including oncogenic signaling pathway activation and
increased migratory potential, but not increased tumorigenicity in vivo. These
findings provide new context for the study and clinical significance of HER2
mutations, in that detailed analysis and study of co-existing mutations in patients
may be required to make meaningful patient management decisions. For
example, our results suggest that HER2-directed therapies such as lapatinib and
neratinib may be effective in reducing cancer migration and not cell proliferation,
but the context of cooperating oncogenic partners must be considered. Taken
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together, our results have relevant translational implications, supporting that
HER2 missense mutations are necessary but not sufficient for imparting features
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